JP2007532638A - Nk1アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用 - Google Patents
Nk1アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用 Download PDFInfo
- Publication number
- JP2007532638A JP2007532638A JP2007508301A JP2007508301A JP2007532638A JP 2007532638 A JP2007532638 A JP 2007532638A JP 2007508301 A JP2007508301 A JP 2007508301A JP 2007508301 A JP2007508301 A JP 2007508301A JP 2007532638 A JP2007532638 A JP 2007532638A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- acid
- substituted
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003772 serotonin uptake inhibitor Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 129
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 20
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 15
- 238000001727 in vivo Methods 0.000 claims abstract description 14
- 239000002243 precursor Substances 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 45
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000001589 carboacyl group Chemical group 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 230000008485 antagonism Effects 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 206010034912 Phobia Diseases 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 208000019899 phobic disease Diseases 0.000 claims description 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 3
- 208000024714 major depressive disease Diseases 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 208000022821 personality disease Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 208000031424 hyperprolactinemia Diseases 0.000 claims description 2
- 208000021267 infertility disease Diseases 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- -1 (substituted) phenyl Chemical group 0.000 abstract description 50
- 239000000203 mixture Substances 0.000 abstract description 36
- 102100024304 Protachykinin-1 Human genes 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 5
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 abstract description 4
- 208000019901 Anxiety disease Diseases 0.000 abstract description 3
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 abstract description 3
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 213
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 125
- 238000001819 mass spectrum Methods 0.000 description 73
- 239000000243 solution Substances 0.000 description 67
- 238000005481 NMR spectroscopy Methods 0.000 description 66
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 62
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 43
- 239000000047 product Substances 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 31
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
- 229910004298 SiO 2 Inorganic materials 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 29
- 239000003039 volatile agent Substances 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 239000011734 sodium Substances 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 25
- 150000001860 citric acid derivatives Chemical class 0.000 description 25
- 238000004587 chromatography analysis Methods 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 239000005909 Kieselgur Substances 0.000 description 22
- 238000001514 detection method Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000006260 foam Substances 0.000 description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000011550 stock solution Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 239000000556 agonist Substances 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- 102400000097 Neurokinin A Human genes 0.000 description 8
- 101800000399 Neurokinin A Proteins 0.000 description 8
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000004808 supercritical fluid chromatography Methods 0.000 description 8
- 239000001569 carbon dioxide Substances 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 7
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- JNZBXZOWYOEPSB-UHFFFAOYSA-N 3-methoxy-4-(methylaminomethyl)naphthalene-2-carbonitrile Chemical compound C1=CC=C2C(CNC)=C(OC)C(C#N)=CC2=C1 JNZBXZOWYOEPSB-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- BRPSJFPPVHYQCL-XEGCMXMBSA-N 2-[(3s)-3-aminopyrrolidin-1-yl]-n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@H](N)C1 BRPSJFPPVHYQCL-XEGCMXMBSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- UOMBYRCKRRIGPC-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-piperazin-1-ylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CCNCC1 UOMBYRCKRRIGPC-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 101800003906 Substance P Proteins 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 4
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000004237 preparative chromatography Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- HPWYTTSVBAFXAB-UHFFFAOYSA-N 2-(dimethylazaniumyl)-2-(4-fluorophenyl)acetate Chemical compound CN(C)C(C(O)=O)C1=CC=C(F)C=C1 HPWYTTSVBAFXAB-UHFFFAOYSA-N 0.000 description 3
- BRPSJFPPVHYQCL-CILPGNKCSA-N 2-[(3r)-3-aminopyrrolidin-1-yl]-n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@@H](N)C1 BRPSJFPPVHYQCL-CILPGNKCSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 102000046798 Neurokinin B Human genes 0.000 description 3
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 3
- 101800002813 Neurokinin-B Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- ITQJDXTZHXDXBU-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(3-methoxyphenyl)-n-methyl-2-pyrrolidin-1-ylacetamide Chemical compound COC1=CC=CC(C(N2CCCC2)C(=O)N(C)CC=2C3=CC=CC=C3C=C(C=2OC)C#N)=C1 ITQJDXTZHXDXBU-UHFFFAOYSA-N 0.000 description 3
- CERXAPSDNGGRJU-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-n-methyl-2-phenyl-2-pyrrolidin-1-ylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC=CC=1)N1CCCC1 CERXAPSDNGGRJU-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- UIEAQPYESKBYOD-RXVAYIKUSA-N tert-butyl n-[(3r)-1-[2-[(3-cyano-2-methoxynaphthalen-1-yl)methyl-methylamino]-1-(4-fluorophenyl)-2-oxoethyl]pyrrolidin-3-yl]-n-methylcarbamate Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@@H](N(C)C(=O)OC(C)(C)C)C1 UIEAQPYESKBYOD-RXVAYIKUSA-N 0.000 description 3
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Substances FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 3
- VLKCFSJJAGBZJR-UHFFFAOYSA-N (3-bromo-2-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)methanol Chemical compound C1CCCC2=C(CO)C(OC)=C(Br)C=C21 VLKCFSJJAGBZJR-UHFFFAOYSA-N 0.000 description 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- BPPAJVJZODQISJ-UHFFFAOYSA-N 1-(3-bromo-2-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-n-methylmethanamine Chemical compound C1CCCC2=CC(Br)=C(OC)C(CNC)=C21 BPPAJVJZODQISJ-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- TXLCONZZXXHPEB-UHFFFAOYSA-N 2-(3-methoxyphenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-ium-1-yl]acetate Chemical compound COC1=CC=CC(C(N2CCN(CC2)C(=O)OC(C)(C)C)C(O)=O)=C1 TXLCONZZXXHPEB-UHFFFAOYSA-N 0.000 description 2
- XTLJQVHECLWGBQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]-(2,2,2-trifluoroacetyl)amino]acetic acid Chemical compound C1N(C(=O)OC(C)(C)C)CCC1N(C(=O)C(F)(F)F)C(C(O)=O)C1=CC=C(F)C=C1 XTLJQVHECLWGBQ-UHFFFAOYSA-N 0.000 description 2
- JRGCYKDBCSGYBO-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]amino]acetic acid Chemical compound C1N(C(=O)OC(C)(C)C)CCC1NC(C(O)=O)C1=CC=C(F)C=C1 JRGCYKDBCSGYBO-UHFFFAOYSA-N 0.000 description 2
- CQFSYUVJYISMEO-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-morpholin-4-ium-4-ylacetate Chemical compound C=1C=C(F)C=CC=1C(C(=O)O)N1CCOCC1 CQFSYUVJYISMEO-UHFFFAOYSA-N 0.000 description 2
- VYVPNTJBGPQTFA-UHFFFAOYSA-N 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 VYVPNTJBGPQTFA-UHFFFAOYSA-N 0.000 description 2
- GFQURFYJCQCOBL-UHFFFAOYSA-N 2-amino-n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(3-methoxyphenyl)-n-methylacetamide Chemical compound COC1=CC=CC(C(N)C(=O)N(C)CC=2C3=CC=CC=C3C=C(C=2OC)C#N)=C1 GFQURFYJCQCOBL-UHFFFAOYSA-N 0.000 description 2
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 2
- XFYCLDGNEKGXRM-UHFFFAOYSA-N 3-ethyl-4-(methylaminomethyl)naphthalene-2-carbonitrile Chemical compound C1=CC=C2C=C(C#N)C(CC)=C(CNC)C2=C1 XFYCLDGNEKGXRM-UHFFFAOYSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 2
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 2
- VVIQUIKUFBRERX-UHFFFAOYSA-N 7-bromo-5-(bromomethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene Chemical compound C1CCCC2=C(CBr)C(OC)=C(Br)C=C21 VVIQUIKUFBRERX-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JQEWJHJDRWNWKV-GEPVFLLWSA-N COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@@H](N(C)C)C1 Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@@H](N(C)C)C1 JQEWJHJDRWNWKV-GEPVFLLWSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102000003141 Tachykinin Human genes 0.000 description 2
- SHDSULLPRKOXFJ-UHFFFAOYSA-N [2-methoxy-3-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalen-1-yl]methanol Chemical compound C1CCCC2=C1C(CO)=C(OC)C(C(F)(F)F)=C2 SHDSULLPRKOXFJ-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- PSIIUQDWRWAEPH-UHFFFAOYSA-N methyl 2-methoxy-3-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalene-1-carboxylate Chemical compound C1CCCC2=CC(C(F)(F)F)=C(OC)C(C(=O)OC)=C21 PSIIUQDWRWAEPH-UHFFFAOYSA-N 0.000 description 2
- CNHWXRCNGMVRNG-UHFFFAOYSA-N methyl 3-bromo-2-methoxy-5,6,7,8-tetrahydronaphthalene-1-carboxylate Chemical compound C1CCCC2=CC(Br)=C(OC)C(C(=O)OC)=C21 CNHWXRCNGMVRNG-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- XZBVLRVWSSHDAI-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(3-methoxyphenyl)-n-methyl-2-piperazin-1-ylacetamide Chemical compound COC1=CC=CC(C(N2CCNCC2)C(=O)N(C)CC=2C3=CC=CC=C3C=C(C=2OC)C#N)=C1 XZBVLRVWSSHDAI-UHFFFAOYSA-N 0.000 description 2
- OMQOSJBGTPJWBW-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-(methylamino)acetamide Chemical compound COC=1C(C#N)=CC2=CC=CC=C2C=1CN(C)C(=O)C(NC)C1=CC=C(F)C=C1 OMQOSJBGTPJWBW-UHFFFAOYSA-N 0.000 description 2
- YOVQEKMOWYBSHB-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-[methyl(prop-2-enyl)amino]acetamide Chemical compound C12=CC=CC=C2C=C(C#N)C(OC)=C1CN(C)C(=O)C(N(C)CC=C)C1=CC=C(F)C=C1 YOVQEKMOWYBSHB-UHFFFAOYSA-N 0.000 description 2
- OFTDQXPEORDFOS-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(dimethylamino)-2-(4-fluorophenyl)-n-methylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(N(C)C)C1=CC=C(F)C=C1 OFTDQXPEORDFOS-UHFFFAOYSA-N 0.000 description 2
- XMLPUJGWJIXTCN-XEGCMXMBSA-N n-[(3s)-1-[2-[(3-cyano-2-methoxynaphthalen-1-yl)methyl-methylamino]-1-(4-fluorophenyl)-2-oxoethyl]pyrrolidin-3-yl]-2,2,2-trifluoroacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@H](NC(=O)C(F)(F)F)C1 XMLPUJGWJIXTCN-XEGCMXMBSA-N 0.000 description 2
- TYXWEBKEPGXMAW-UHFFFAOYSA-N n-[2-[(3-cyano-2-methoxynaphthalen-1-yl)methyl-methylamino]-1-(4-fluorophenyl)-2-oxoethyl]-2,2,2-trifluoro-n-(1-methylpyrrolidin-3-yl)acetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N(C(=O)C(F)(F)F)C1CCN(C)C1 TYXWEBKEPGXMAW-UHFFFAOYSA-N 0.000 description 2
- ZXLLVFHIFAJCPX-UHFFFAOYSA-N n-[2-[(3-cyano-2-methoxynaphthalen-1-yl)methyl-methylamino]-1-(4-fluorophenyl)-2-oxoethyl]-2,2,2-trifluoro-n-pyrrolidin-3-ylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N(C(=O)C(F)(F)F)C1CCNC1 ZXLLVFHIFAJCPX-UHFFFAOYSA-N 0.000 description 2
- DTSXNNQTQXRZHV-UHFFFAOYSA-N n-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(3-methoxyphenyl)-n-methyl-2-morpholin-4-ylacetamide Chemical compound COC1=CC=CC(C(N2CCOCC2)C(=O)N(C)CCC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 DTSXNNQTQXRZHV-UHFFFAOYSA-N 0.000 description 2
- HBRYSSFAIJEGLG-UHFFFAOYSA-N n-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-n-methyl-2-morpholin-4-ylacetamide Chemical compound C1COCCN1C(C=1C=CC(F)=CC=1)C(=O)N(C)CCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HBRYSSFAIJEGLG-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108060008037 tachykinin Proteins 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- 125000004747 1,1-dimethylethoxycarbonyl group Chemical group CC(C)(OC(=O)*)C 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- AKXYSLROMYPJOX-UHFFFAOYSA-N 1-[2-methoxy-3-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalen-1-yl]-n-methylmethanamine Chemical compound C1CCCC2=CC(C(F)(F)F)=C(OC)C(CNC)=C21 AKXYSLROMYPJOX-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- CTTUQCIBNSCQRH-UHFFFAOYSA-N 2,3,4-trimethylpentan-3-amine Chemical compound CC(C)C(C)(N)C(C)C CTTUQCIBNSCQRH-UHFFFAOYSA-N 0.000 description 1
- HJGSVCWZTYWUFA-UHFFFAOYSA-N 2-(3-acetamidoazetidin-1-yl)-n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC(NC(C)=O)C1 HJGSVCWZTYWUFA-UHFFFAOYSA-N 0.000 description 1
- UOYBISSDVZCKEW-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-2-(3-methoxyphenyl)acetic acid Chemical compound COC1=CC=CC(C(N2CCC(F)(F)CC2)C(O)=O)=C1 UOYBISSDVZCKEW-UHFFFAOYSA-N 0.000 description 1
- RBVUICOGSFFJQN-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-ium-1-yl]acetate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(C(O)=O)C1=CC=C(F)C=C1 RBVUICOGSFFJQN-UHFFFAOYSA-N 0.000 description 1
- WLJMDSMSZOEVNJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-pyrrolidin-1-ylacetic acid Chemical compound C=1C=C(F)C=CC=1C(C(=O)O)N1CCCC1 WLJMDSMSZOEVNJ-UHFFFAOYSA-N 0.000 description 1
- SSOJFJWJYPYDND-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[[2-methoxy-3-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalen-1-yl]methyl]-n-methyl-2-piperazin-1-ylacetamide Chemical compound C1=2CCCCC=2C=C(C(F)(F)F)C(OC)=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CCNCC1 SSOJFJWJYPYDND-UHFFFAOYSA-N 0.000 description 1
- CHEVEUQAQSAKMF-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-methyl-2-piperazin-1-ylacetamide Chemical compound C=1C=C(F)C=CC=1C(C(=O)NC)N1CCNCC1 CHEVEUQAQSAKMF-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JDQNEPNVWWMTEU-BXXZMZEQSA-N 2-[(3s)-3-[acetyl(methyl)amino]pyrrolidin-1-yl]-n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@H](N(C)C(C)=O)C1 JDQNEPNVWWMTEU-BXXZMZEQSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WYVXVJWUTRMVEB-UHFFFAOYSA-N 2-[[2-[(3-cyano-2-methoxynaphthalen-1-yl)methyl-methylamino]-1-(4-fluorophenyl)-2-oxoethyl]-methylamino]acetic acid Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(N(C)CC(O)=O)C1=CC=C(F)C=C1 WYVXVJWUTRMVEB-UHFFFAOYSA-N 0.000 description 1
- JXMBBBHURQYWSG-UHFFFAOYSA-N 2-amino-n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(N)C1=CC=C(F)C=C1 JXMBBBHURQYWSG-UHFFFAOYSA-N 0.000 description 1
- PVUBMUQYUKWQKR-UHFFFAOYSA-N 3-ethyl-4-(iodomethyl)naphthalene-2-carbonitrile Chemical compound C1=CC=CC2=C(CI)C(CC)=C(C#N)C=C21 PVUBMUQYUKWQKR-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- OABUKBBBSMNNPM-UHFFFAOYSA-N 4,4-difluoropiperidin-1-ium;chloride Chemical compound Cl.FC1(F)CCNCC1 OABUKBBBSMNNPM-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- PQUZDTSQWDVTGK-UHFFFAOYSA-N 4-(iodomethyl)-3-methoxynaphthalene-2-carbonitrile Chemical compound C1=CC=CC2=C(CI)C(OC)=C(C#N)C=C21 PQUZDTSQWDVTGK-UHFFFAOYSA-N 0.000 description 1
- ZFEDCJCKCCNRMW-UHFFFAOYSA-N 5-(bromomethyl)-6-methoxy-7-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene Chemical compound C1CCCC2=C1C(CBr)=C(OC)C(C(F)(F)F)=C2 ZFEDCJCKCCNRMW-UHFFFAOYSA-N 0.000 description 1
- ICZHJFWIOPYQCA-YVHRXSIGSA-N 9-(1-deuteriooxy-2,2,2-trifluoroethyl)anthracene Chemical compound C1=CC=C2C(C(O[2H])C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 ICZHJFWIOPYQCA-YVHRXSIGSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 0 C*c1c(CN(C)C(C(c(cc2)ccc2F)NC)=O)c(cccc2)c2cc1C#N Chemical compound C*c1c(CN(C)C(C(c(cc2)ccc2F)NC)=O)c(cccc2)c2cc1C#N 0.000 description 1
- BRPSJFPPVHYQCL-UHFFFAOYSA-N CN(Cc(c(cccc1)c1cc1C#N)c1OC)C(C(c(cc1)ccc1F)N(CC1)CC1N)=O Chemical compound CN(Cc(c(cccc1)c1cc1C#N)c1OC)C(C(c(cc1)ccc1F)N(CC1)CC1N)=O BRPSJFPPVHYQCL-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 101100491597 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-6 gene Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- OAXAGJOHASILBU-UHFFFAOYSA-N butyl-hydroxy-phenyl-sulfanylidene-$l^{5}-phosphane Chemical compound CCCCP(O)(=S)C1=CC=CC=C1 OAXAGJOHASILBU-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- LBERIROBKALHRW-UHFFFAOYSA-N methyl 2-[[2-[(3-cyano-2-methoxynaphthalen-1-yl)methyl-methylamino]-1-(4-fluorophenyl)-2-oxoethyl]amino]acetate Chemical compound COC=1C(C#N)=CC2=CC=CC=C2C=1CN(C)C(=O)C(NCC(=O)OC)C1=CC=C(F)C=C1 LBERIROBKALHRW-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- MWTJAWVXUVUAOQ-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(3-methoxyphenyl)-n-methyl-2-(4-methylpiperazin-1-yl)acetamide Chemical compound COC1=CC=CC(C(N2CCN(C)CC2)C(=O)N(C)CC=2C3=CC=CC=C3C=C(C=2OC)C#N)=C1 MWTJAWVXUVUAOQ-UHFFFAOYSA-N 0.000 description 1
- OXKKZAJJPWGUDA-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-ethylpiperazin-1-yl)-2-(4-fluorophenyl)-n-methylacetamide Chemical compound C1CN(CC)CCN1C(C=1C=CC(F)=CC=1)C(=O)N(C)CC1=C(OC)C(C#N)=CC2=CC=CC=C12 OXKKZAJJPWGUDA-UHFFFAOYSA-N 0.000 description 1
- DYUDDAAPWMJFCE-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-2-(2-hydroxyethylamino)-n-methylacetamide Chemical compound C12=CC=CC=C2C=C(C#N)C(OC)=C1CN(C)C(=O)C(NCCO)C1=CC=C(F)C=C1 DYUDDAAPWMJFCE-UHFFFAOYSA-N 0.000 description 1
- YPJZRMKQDYIHBP-RIBGEGAISA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-2-[(3r)-3-[(2-methoxyacetyl)-methylamino]pyrrolidin-1-yl]-n-methylacetamide Chemical compound C1[C@H](N(C)C(=O)COC)CCN1C(C=1C=CC(F)=CC=1)C(=O)N(C)CC1=C(OC)C(C#N)=CC2=CC=CC=C12 YPJZRMKQDYIHBP-RIBGEGAISA-N 0.000 description 1
- NWRVKEIJIVMWPR-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-[(1-methylpyrrolidin-3-yl)amino]acetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)NC1CCN(C)C1 NWRVKEIJIVMWPR-UHFFFAOYSA-N 0.000 description 1
- QORSHHXYIFQMDF-ALLRNTDFSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-[(3s)-3-morpholin-4-ylpyrrolidin-1-yl]acetamide Chemical compound N1([C@H]2CCN(C2)C(C(=O)N(C)CC2=C3C=CC=CC3=CC(=C2OC)C#N)C=2C=CC(F)=CC=2)CCOCC1 QORSHHXYIFQMDF-ALLRNTDFSA-N 0.000 description 1
- WJLPGIKIZATSKW-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]acetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CCN(C(=O)C(F)(F)F)CC1 WJLPGIKIZATSKW-UHFFFAOYSA-N 0.000 description 1
- DQQGYEJWIHLTDS-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-[methyl(pyrrolidin-3-yl)amino]acetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N(C)C1CCNC1 DQQGYEJWIHLTDS-UHFFFAOYSA-N 0.000 description 1
- UMRZIBPYNQYNME-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-morpholin-4-ylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CCOCC1 UMRZIBPYNQYNME-UHFFFAOYSA-N 0.000 description 1
- LMACTHNTGLIAAD-UHFFFAOYSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-(4-fluorophenyl)-n-methyl-2-pyrrolidin-1-ylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CCCC1 LMACTHNTGLIAAD-UHFFFAOYSA-N 0.000 description 1
- NPUWAFLQAGLEOW-UHFKCPIBSA-N n-[(3-cyano-2-methoxynaphthalen-1-yl)methyl]-2-[(3s)-3-(2,5-dioxopyrrolidin-1-yl)pyrrolidin-1-yl]-2-(4-fluorophenyl)-n-methylacetamide Chemical compound N1([C@H]2CCN(C2)C(C(=O)N(C)CC2=C3C=CC=CC3=CC(=C2OC)C#N)C=2C=CC(F)=CC=2)C(=O)CCC1=O NPUWAFLQAGLEOW-UHFKCPIBSA-N 0.000 description 1
- HXSLIWNINUNHIA-XADRRFQNSA-N n-[(3s)-1-[2-[(3-cyano-2-methoxynaphthalen-1-yl)methyl-methylamino]-1-(4-fluorophenyl)-2-oxoethyl]pyrrolidin-3-yl]-2,2,2-trifluoro-n-methylacetamide Chemical compound COC1=C(C#N)C=C2C=CC=CC2=C1CN(C)C(=O)C(C=1C=CC(F)=CC=1)N1CC[C@H](N(C)C(=O)C(F)(F)F)C1 HXSLIWNINUNHIA-XADRRFQNSA-N 0.000 description 1
- CLRXDYYWVSSHCG-UHFFFAOYSA-N n-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-n-methyl-2-(3-morpholin-4-ylazetidin-1-yl)acetamide Chemical compound C1C(N2CCOCC2)CN1C(C=1C=CC(F)=CC=1)C(=O)N(C)CCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CLRXDYYWVSSHCG-UHFFFAOYSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- CUNPJFGIODEJLQ-UHFFFAOYSA-M potassium;2,2,2-trifluoroacetate Chemical compound [K+].[O-]C(=O)C(F)(F)F CUNPJFGIODEJLQ-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- DQQJBEAXSOOCPG-SSDOTTSWSA-N tert-butyl n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCNC1 DQQJBEAXSOOCPG-SSDOTTSWSA-N 0.000 description 1
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical group CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 1
- MHKPBRDUFKYAGW-UHFFFAOYSA-N tert-butyl n-piperazin-1-ylcarbamate Chemical compound CC(C)(C)OC(=O)NN1CCNCC1 MHKPBRDUFKYAGW-UHFFFAOYSA-N 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- PNQBEPDZQUOCNY-UHFFFAOYSA-N trifluoroacetyl chloride Chemical compound FC(F)(F)C(Cl)=O PNQBEPDZQUOCNY-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400969A SE0400969D0 (sv) | 2004-04-14 | 2004-04-14 | Aryl glycine derivatives and their use |
| SE0400967A SE0400967D0 (sv) | 2004-04-14 | 2004-04-14 | Aryl glycinamide derivatives and their use |
| PCT/SE2005/000501 WO2005100325A1 (en) | 2004-04-14 | 2005-04-06 | Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532638A true JP2007532638A (ja) | 2007-11-15 |
| JP2007532638A5 JP2007532638A5 (https=) | 2008-05-29 |
Family
ID=35149928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508301A Pending JP2007532638A (ja) | 2004-04-14 | 2005-04-06 | Nk1アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070203139A1 (https=) |
| EP (1) | EP1740553A1 (https=) |
| JP (1) | JP2007532638A (https=) |
| WO (1) | WO2005100325A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532633A (ja) * | 2004-04-13 | 2007-11-15 | コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー | インデン誘導体及びその製造方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014181788A1 (ja) * | 2013-05-08 | 2014-11-13 | キッセイ薬品工業株式会社 | α-置換グリシンアミド誘導体 |
| WO2024121129A1 (en) * | 2022-12-05 | 2024-06-13 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5555166A (en) * | 1978-10-18 | 1980-04-22 | Basf Ag | Alphaaazolyllalphaaphenyllacetic acid derivative*its manufacture and bactericide containing it |
| JPS5852256A (ja) * | 1981-09-24 | 1983-03-28 | Nippon Nohyaku Co Ltd | 置換又は非置換脂肪酸アミド誘導体及びその塩類 |
| JPH05294915A (ja) * | 1992-04-21 | 1993-11-09 | Yamanouchi Pharmaceut Co Ltd | タキキニン拮抗剤 |
| JPH0692921A (ja) * | 1992-07-27 | 1994-04-05 | Kyorin Pharmaceut Co Ltd | 新規なアリールグリシンアミド誘導体及びその製造法 |
| JPH07206806A (ja) * | 1993-12-21 | 1995-08-08 | Bristol Myers Squibb Co | β3アゴニストとして有用なカテコールアミン代用物 |
| JPH08119923A (ja) * | 1994-08-19 | 1996-05-14 | Sanofi Sa | グリシンアミド誘導体、その製法およびそれを含有する医薬 |
| JP2000506150A (ja) * | 1996-03-06 | 2000-05-23 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | 新規なアリールグリシンアミド誘導体、その製造方法及び該誘導体を含む医薬組成物 |
| JP2000239243A (ja) * | 1999-02-18 | 2000-09-05 | Pfizer Prod Inc | 神経ペプチドyアンタゴニスト |
| JP2002517386A (ja) * | 1998-05-30 | 2002-06-18 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | 新規なニューロキニン拮抗物質、その調製方法及びその化合物を含む医薬組成物 |
| WO2002076925A2 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| WO2004004724A1 (de) * | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue arzneimittelkompositionen auf der basis neuer anticholinergika und nk1-rezeptor-antagonisten |
| JP2007520543A (ja) * | 2004-02-04 | 2007-07-26 | ファイザー・プロダクツ・インク | 置換キノリン化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2123403C (en) * | 1991-11-12 | 2002-02-05 | Brian T. O'neill | Acyclic ethylenediamine derivatives as substance p receptor antagonists |
| US5696123A (en) * | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
| TW449590B (en) * | 1995-04-14 | 2001-08-11 | Boehringer Ingelheim Kg | New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds |
| US6946542B2 (en) * | 2002-04-01 | 2005-09-20 | University Of Southern California | Amino amides, peptides and peptidomimetics |
-
2005
- 2005-04-06 WO PCT/SE2005/000501 patent/WO2005100325A1/en not_active Ceased
- 2005-04-06 JP JP2007508301A patent/JP2007532638A/ja active Pending
- 2005-04-06 EP EP05730884A patent/EP1740553A1/en not_active Withdrawn
- 2005-04-06 US US10/599,823 patent/US20070203139A1/en not_active Abandoned
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5555166A (en) * | 1978-10-18 | 1980-04-22 | Basf Ag | Alphaaazolyllalphaaphenyllacetic acid derivative*its manufacture and bactericide containing it |
| JPS5852256A (ja) * | 1981-09-24 | 1983-03-28 | Nippon Nohyaku Co Ltd | 置換又は非置換脂肪酸アミド誘導体及びその塩類 |
| JPH05294915A (ja) * | 1992-04-21 | 1993-11-09 | Yamanouchi Pharmaceut Co Ltd | タキキニン拮抗剤 |
| JPH0692921A (ja) * | 1992-07-27 | 1994-04-05 | Kyorin Pharmaceut Co Ltd | 新規なアリールグリシンアミド誘導体及びその製造法 |
| JPH07206806A (ja) * | 1993-12-21 | 1995-08-08 | Bristol Myers Squibb Co | β3アゴニストとして有用なカテコールアミン代用物 |
| JPH08119923A (ja) * | 1994-08-19 | 1996-05-14 | Sanofi Sa | グリシンアミド誘導体、その製法およびそれを含有する医薬 |
| JP2000506150A (ja) * | 1996-03-06 | 2000-05-23 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | 新規なアリールグリシンアミド誘導体、その製造方法及び該誘導体を含む医薬組成物 |
| JP2002517386A (ja) * | 1998-05-30 | 2002-06-18 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | 新規なニューロキニン拮抗物質、その調製方法及びその化合物を含む医薬組成物 |
| JP2000239243A (ja) * | 1999-02-18 | 2000-09-05 | Pfizer Prod Inc | 神経ペプチドyアンタゴニスト |
| WO2002076925A2 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| WO2004004724A1 (de) * | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue arzneimittelkompositionen auf der basis neuer anticholinergika und nk1-rezeptor-antagonisten |
| JP2007520543A (ja) * | 2004-02-04 | 2007-07-26 | ファイザー・プロダクツ・インク | 置換キノリン化合物 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532633A (ja) * | 2004-04-13 | 2007-11-15 | コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー | インデン誘導体及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1740553A1 (en) | 2007-01-10 |
| WO2005100325A1 (en) | 2005-10-27 |
| US20070203139A1 (en) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4853918B2 (ja) | グリシン輸送阻害剤としての三環式化合物の使用 | |
| US8912220B2 (en) | Compounds and methods of use thereof | |
| JP5853035B2 (ja) | β−セクレターゼ(BACE)の阻害剤として有用な3,4−ジヒドロ−ピロロ[1,2−a]ピラジン−1−イルアミン誘導体 | |
| WO2007099423A1 (en) | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists | |
| IL109234A (en) | Indole derivatives, their preparation and pharmaceutical compositions containing them | |
| IE922464A1 (en) | New benzimidazolone derivatives | |
| JP7445325B2 (ja) | 疾患の処置のための複素環化合物 | |
| JP2013540740A (ja) | ベータ−セクレターゼ(BACE)の阻害剤として有用な4,7−ジヒドロ−ピラゾロ[1,5−a]ピラジン−6−イルアミン誘導体 | |
| MX2014006689A (es) | Derivados de 6-difluorometil-5,6-dihidro-2h-[1,4]oxazin-3-amina. | |
| JP2006502157A (ja) | ナフチルエーテル化合物及びそれらの使用 | |
| JP5062938B2 (ja) | セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規n,n’−二置換ベンゾイミダゾロン誘導体 | |
| JP2007532638A (ja) | Nk1アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用 | |
| JP3830378B2 (ja) | アシルアミノシクロプロパン誘導体 | |
| US20050282811A1 (en) | Diazabicyclic histamine-3 receptor antagonists | |
| JP2006502239A (ja) | ナフトアミド誘導体およびその使用 | |
| WO2009119528A1 (ja) | 複素環化合物 | |
| US6432946B1 (en) | 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands | |
| US20060058352A1 (en) | Piperidine amine compounds and their use | |
| JP2007532636A (ja) | Nk1アンタゴニスト及びセロトニン再取り込み阻害剤としての2−(アリールアルコキシ)−1−フェニルエチルアミン誘導体 | |
| CN121941676A (zh) | Pde7调节剂化合物 | |
| WO1999064396A1 (en) | Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands | |
| WO2000012500A2 (en) | 2-aryl-4-(1-[4-heteroaryl]piperazin-1-yl) methylimidazoles: dopamine d4 receptor subtype ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080404 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080404 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110509 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110516 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111018 |